StockMacro
Menu

Dror Bashan

Insider (Form 4 reporting owner): PRESIDENT AND CEO CIK 1781450Name as filed: Bashan DrorIts filings on EDGARAll insiders

Measures activity, not value. Not investment advice.

Since 11 Apr 2022, bought $294K in 3 open-market purchases of Protalix BioTherapeutics.

Companies

Role on the latest Form 4 for each; open-market trades counted
CompanyRoleTrades fromtoPurchasesSales
Protalix BioTherapeutics PLXPRESIDENT AND CEO11 Apr 202219 Dec 20253$294K–

What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.

Median return minus the sector fund, in percentage points; "too few trades" under 5
Open-market tradesAfter 3 monthsAfter 6 monthsAfter 12 months
After purchasestoo few trades3 tradestoo few trades3 tradestoo few trades2 trades

For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.

By year

Counted open-market trades, by trade date
YearPurchasesBoughtSalesSoldNet
20251$101K––$101K
20231$90K––$90K
20221$102K––$102K

Every trade

3, newest first; open-market purchases and sales only
Trade dateCompanySideSharesPriceValuePlanned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. Filing
19 Dec 2025Protalix BioTherapeutics PLXBuy56,000$1.81$101KNoForm 4filed 23 Dec 2025
19 Oct 2023Protalix BioTherapeutics PLXBuy64,516$1.40$90KNoForm 4filed 20 Oct 2023
11 Apr 2022Protalix BioTherapeutics PLXBuy68,000$1.50$102KNot statedForm 4filed 13 Apr 2022

From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.